key: cord-0967354-gg63yji0 authors: Dilogo, Ismail Hadisoebroto; Aditianingsih, Dita; Sugiarto, Adhrie; Burhan, Erlina; Damayanti, Triya; Sitompul, Pompini Agustina; Mariana, Nina; Antarianto, Radiana D.; Liem, Isabella Kurnia; Kispa, Tera; Mujadid, Fajar; Novialdi, Novialdi; Luviah, Evah; Kurniawati, Tri; Lubis, Andri M. T.; Rahmatika, Dina title: Umbilical cord mesenchymal stromal cells as critical COVID‐19 adjuvant therapy: A randomized controlled trial date: 2021-06-08 journal: Stem Cells Transl Med DOI: 10.1002/sctm.21-0046 sha: a02938142db2fc052a6b25519b7a287349224756 doc_id: 967354 cord_uid: gg63yji0 One of the main causes of acute respiratory distress syndrome in coronavirus disease 2019 (COVID‐19) is cytokine storm, although the exact cause is still unknown. Umbilical cord mesenchymal stromal cells (UC‐MSCs) influence proinflammatory T‐helper 2 (Th(2)) cells to shift to an anti‐inflammatory agent. To investigate efficacy of UC‐MSC administration as adjuvant therapy in critically ill patients with COVID‐19, we conducted a double‐blind, multicentered, randomized controlled trial at four COVID‐19 referral hospitals in Jakarta, Indonesia. This study included 40 randomly allocated critically ill patients with COVID‐19; 20 patients received an intravenous infusion of 1 × 10(6)/kg body weight UC‐MSCs in 100 ml saline (0.9%) solution (SS) and 20 patients received 100 ml 0.9% SS as the control group. All patients received standard therapy. The primary outcome was measured by survival rate and/or length of ventilator usage. The secondary outcome was measured by clinical and laboratory improvement, with serious adverse events. Our study showed the survival rate in the UC‐MSCs group was 2.5 times higher than that in the control group (P = .047), which is 10 patients and 4 patients in the UC‐MSCs and control groups, respectively. In patients with comorbidities, UC‐MSC administration increased the survival rate by 4.5 times compared with controls. The length of stay in the intensive care unit and ventilator usage were not statistically significant, and no adverse events were reported. The application of infusion UC‐MSCs significantly decreased interleukin 6 in the recovered patients (P = .023). Therefore, application of intravenous UC‐MSCs as adjuvant treatment for critically ill patients with COVID‐19 increases the survival rate by modulating the immune system toward an anti‐inflammatory state. Application of intravenous umbilical cord mesenchymal stromal cell infusion as an adjuvant treatment for critically ill patients with COVID-19 increases the survival rate by modulating the immune system toward an anti-inflammatory state. There are some unfortunate patients with COVID-19 who are not responsive to all the combination treatment given. Therefore, this study exclusively involved intubated critically ill patients with COVID-19 in the intensive care unit. In contrast to existing studies, this study used regular umbilical cord mesenchymal stem cells without a special manipulation procedure that was directed at achieving angiotensin converting enzyme-2 (ACE 2)-negative mesenchymal stem cell. The results showed that the survival rate in those receiving umbilical cord mesenchymal stromal cells was 2.5 times higher than that in the control group. Patients with COVID-19 are increasing around the world, with more than 61.8 million cumulative cases and 1.4 million deaths globally. In November 2020, a referral hospital's data in Jakarta showed that intensive care unit (ICU) occupancy had increased from 60% to 80%. Moreover, the mortality rate of critically ill patients with COVID-19-related pneumonia in the ICU was as high as 87% in a top referral COVID-19 hospital (Persahabatan Central Hospital, Jakarta, Indonesia); this situation necessitated that clinicians fashion a breakthrough therapy to increase the survival of patients in the ICU. The current management of COVID-19 serves as an empiric and supportive therapy, as the curative regiment has yet to be found. Unfortunately, some patients are not responsive despite all the combination treatments given. There is still very limited research about the new potential therapeutic agents for treating critically ill patients with COVID-19. 1, 2 Acute respiratory distress syndrome (ARDS) is the leading cause of death in patients with COVID-19, and one of the main causes of ARDS in SARS-CoV-2 infection is cytokine storm, although this topic is still a matter of controversy. 3 In interactions with dendritic cells, mesenchymal stromal cells (MSCs) cause proinflammatory Th 2 cells to shift to anti-inflammatory Th 2 cells, including changes in cytokine profiles toward anti-inflammatory. Human umbilical cord mesenchymal stromal cells (hUC-MSCs) have a high proliferative capacity for sustaining paracrine effects and low risk of body rejection due to absent Human Leukocyte Antigen (HLA) expression. 4, 5 Clinical trials in China have shown that patients with COVID-19-related pneumonia treated with UC-MSCs were more likely to survive and have a faster recovery than patients without MSC therapy. [6] [7] [8] In contrast to existing studies, our study exclusively involved intubated critically ill patients with COVID-19 in the ICU and used naïve umbilical cord mesenchymal stromal cells that were processed using the simple multiple harvest explant procedure methods without a special manipulation procedure that was directed at achieving ACE-2 negative MSCs. Therefore, this study aims to investigate whether administration of allogenic UC-MSCs as adjuvant therapy for critically ill patients with COVID-19 who are unresponsive to conventional supportive treatment can improve the survival rate of critically ill patients with COVID-19-related pneumonia in Indonesia. This is a multicentered, double-blind, randomized clinical trial, con- Subjects in this study were selected using stratified random sampling and randomized using a computerized random number generator. A total of 40 subjects were included, with 20 in the control group and 20 in the experimental group. The number of subjects from this study was determined based on references to previous studies. This is a double-blinded study. Neither the subjects nor the care providers and those assessing the outcomes were aware of the treatment assignment. This is achieved by making the packaging of MSCs and the placebo in an identical way. All patient allocations were determined from a third party that was unrelated to clinical decision-making or data collection. Critically ill patients with COVID-19-related pneumonia were defined as those who were intubated with severe pneumonia clinically and radiologically, confirmed by a positive result in Reverse Transcription -Polymerase Chain Reaction (RT-PCR) swab from nasopharyngeal or bronchoalveolar lavage. The criteria of critical patients included the following: (a) respiratory failure that progressed into ARDS, defined as the partial pressure of oxygen in arterial blood (PaO 2 )/the fraction of inspired oxygen (FiO 2 ) lower than 300 mmHg and supported by mechanical ventilation; (b) shock, such as septic shock (persistent hypotension following fluid resuscitation and requiring vasopressor to maintain mean arterial pressure of ≥65 mmHg and serum lactate of >2 mmol/L); (c) multiple organ failure and monitored in the ICU. In this study, inclusion criteria for the participant were (a) age 18-95 years, (b) critically ill patients with RT-PCR-confirmed COVID-19 obtained from a nasopharyngeal swab or bronchoalveolar lavage if intubated, (c) leukopenia and lymphopenia in peripheral blood and differential count, (d) presenting with pneumonia on chest x-ray and/or ground-glass opacity on thorax computed tomography (CT) scan, and (e) signed informed consent by subjects or family members. Exclusion criteria in this study were (a) any history of malignancy, (<2%) were found on cells acquired starting from passage 3, signifying the presence of MSCs. Our previous study showed that senescence is observed after passage 10 and viability is observed until passage 18 for UC-MSCs. 9 After baseline assessments were done, subjects admitted to the study were given a single intravenous infusion of 1 Â 10 6 /kg body weight UC-MSCs in 100 ml saline (0.9%) solution for the experimental group or with placebo (100 ml saline [0.9%] solution) for the control group on day 8 (ranged from day 2-30) of treatment in the ICU. Baseline parameters including routine blood count, differential count, C-Reactive Protein (CRP), D-dimer, fibrinogen, and procalcitonin, and specific markers, including vascular endothelial growth factor (VEGF), ferritin, cytokine IL-6, IL-10, flow cytometry leukemia inhibitory factor (LIF), and lymphocyte subpopulation CX-CR3 CD4, CD8, and CD56, were assessed before the application was done. During 15 days of observation, laboratory evaluations were conducted on day 0 and day 1 and then once every 3 days for routine laboratory examination whereas specific markers were evaluated on day 0 and day 7 only. Adverse events (AEs) were closely observed in the MSCs group. The primary outcome is assessed by mortality rate and length of ventilator usage. We measured the onset of intubation, which was defined by the length of ventilator usage during the patient's care. The period of intubation until the application of allogeneic UC-MSCs was defined by the period of the patient still needing mechanical ventilation after being given intervention. Secondary outcomes were measured by (a) length of stay in the ICU; (b) improvement in the routine laboratory value, including routine blood count, differential count, CRP, D-dimer, fibrinogen, and procalcitonin; (c) improvement in biomarker laboratory value of cytokines and lymphocyte subpopulation (VEGF, ferritin, IL-6, LIF, CX-CR3 CD4, CD8, CD56 cell); and (d) AE or serious AE (SAE). Descriptive statistics were used to describe demographic and parameter characteristics, including mean, SD, frequencies, and percentages. The rate of change in laboratory value was calculated for each parameter and compared between the control and experiment groups using the Mann-Whitney-U test. Internal analysis of the experiment group was done in patients treated with MSCs, comparing the value before and after treatment using the Wilcoxon signed-rank test. P values <.05 were considered statistically significant. The survival analysis was assessed using Cox regression. The analysis was performed using SPSS ver. 25 (IBM, Armonk, NY). A total of 40 critically ill patients with COVID-19-related pneumonia were included. No patients were excluded or dropped out of the trial. The baseline characteristics of the 40 patients are summarized in Table 1 . Of the 40 subjects, males (75%) were significantly affected compared with females (P = .049). The mortality rate was 65% (n = 26) and the survival rate was 35% (n = 14), in which 71.4% (n = 10) of the recovered group were from the MSCs group and 28.6% (n = 4) were from the control group. Thus, the survival rate in the MSCs group was 2.5 times higher than that in the control group (P = .047). When only analyzing patients with comorbidities, our study showed that UC-MSC administration increased the survival rate by 4.5 times compared with controls, which is nine patients and two patients in the MSCs and control group, respectively. The outcome of the subjects is described in Table 2 . There were 19 subjects (47.5%) who had >2 comorbidities. These subjects had a higher mortality rate than those with <2 comorbidities (79.17% died). The majority of those with >2 comorbidities who recovered came from the MSCs group, with a 4:1 ratio to the control group. Furthermore, there was a significant difference between the subject outcome and the number of comorbidities (P = .023). In the distribution of comorbidities among subjects who died, 65% of subjects had diabetes mellitus, 46.15% had hypertension, 26.93% had chronic kidney disease, 15.38% had coronary artery disease, 7.69% had congestive heart failure, and 7.69% had tuberculosis. Three there were no significant differences in the complete blood count (hemoglobin, hematocrit, leukocyte, lymphocyte, and thrombocyte between the MSCs group and the control group with P value, respectively: .630; .782; .423; .414; .295). There was no significant difference between D-dimer and fibrinogen in the MSCs group vs the control group (P value, respectively: .233; .979). Inflammatory markers, namely, procalcitonin, and CRP were not significantly different between the MSCs group and the control group (P value, respectively: .212; .827; .707). Ten subjects (62.5%) in the control group had a reduced value of IL-10, whereas most of the subjects in the MSCs group showed an increased IL-10 value on the seventh day after MSC application with no significant difference between groups (P = .661). However, an increased value from day 0 to day 7 was observed, from an average 3.26 pg/ml to 4.70 pg/ml in the MSCs group. There was a decreased trend in IL-6 after MSC application; in contrast, an increasing trend was observed in the control group. The application of infusion UC-MSCs significantly decreased IL-6 in the recovered patients (P = .023). The trend of cytokine analysis is shown in Figure 3 . VEGF also showed an increasing trend in the MSCs group, compared with a decreased trend in the control group on day 7, but there was no significant difference (P = .826). A significant increase in LIF value was also observed in subjects receiving MSC application (P = .002). Ferritin was also reduced in the MSCs group but increased in the control group, however, the difference was not statistically significant (P = .861). Details of the cytokine analysis are presented in Table 3 . We examined lymphocyte subpopulations (Supplemental Figure 1) , namely, CD4-CXCR3, CD8-CXCR3, and CD56-CXCR3 (Supplemental Figure 2 ). We found that MSCs were better in suppressing the population of CD8-CXCR3 and CD56-CXCR3 among critically ill subjects, but no significant difference between groups was detected (P = .061). CD4-CXCR3 analysis revealed that there was also no significant difference between the MSCs and control group during the baseline and day 7 evaluation (P value, respectively: .064; .745) (Supplemental Table 1 ). The intravenous infusion of MSCs was found to be safe and well tol- Cytokine P value (before application in total subjects) P value (7 days after application in total subjects) P value (7 days after application in subjects who recovered) P value (7 days after application in subjects who died) thrombin-antithrombin-complex and D-dimer after administration of 4 Â 10 6 cells/kg body weight AT-MSCs; thus, an application dose less than 4 Â 10 6 cells/kg body weight is recommended. 16 Not analyzing the TF/CD142, we used UC-MSCs with 1 Â 10 6 /kg body weight dose. Supported with no significant differences in the D-dimer between two groups at baseline and after application, the use of MSCs in this study is not associated with hypercoagulation. 17 Our study revealed that there was a decreased trend of IL with no statistically significant value. 18, 19 Consistently, Leng et al. reported an increase of IL-10 in the MSCs group compared with the placebo group with a significant value (P < .05). Having the ability to secrete paracrine factors that suppress IL-6 serum level, MSCs evoked the tolerance state by which proinflammatory cytokine subsides. 20 Indeed, our result showed IL-10 increment on day 7 after MSC application in comparison to baseline. Released by MSCs, IL-10 activated T-lymphocyte suppressor or regulator and also play roles in the healing of the organ tissue. [21] [22] [23] [24] Increased expression of LIF in our study was shown in 80% of MSCs have been indicated to regulate the balance between proinflammatory (Th1) and anti-inflammatory(Th 2 ), and a shift toward Th 2 phenotype is the target of MSC application. [30] [31] [32] We also studied VEGF, an angiogenic factor that is essential in the recovery of the damaged lung. Whereas VEGF tended to go down in the control group, MSCs gave a boost to increase VEGF in the circulation so that regeneration of capillary at the lung could occur. 23 Another limitation is that we did not apply exact criteria about how long the critically ill patient with COVID-19 had been treated in the ICU. Application of intravenous infusion MSCs as an adjuvant treatment for critically ill patients with COVID-19 increases the survival rate by modulating the immune system toward an anti-inflammatory state. conception and design, administrative support; D.R.: conception and design, administrative support, assembly of data, data analysis, manuscript writing. The data contained in this study will be accessible with the publication of this article. Data can be accessed by other researchers who is doing a related research has received permission to request data. Data can be requested by directly emailing the corrseponding author. Ismail Hadisoebroto Dilogo https://orcid.org/0000-0002-6202- Overview of stem cell therapy for acute respiratory distress syndrome with focus on COVID 19 Pathological findings of COVID-19 associated with acute respiratory distress syndrome Clinical features of patients infected with 2019 novel coronavirus in Wuhan Treatment of cytokine storm in COVID-19 patients with immunomodulatory therapy Stem cells therapy as a possible therapeutic option in treating COVID-19 patients Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells Human umbilical cord mesenchymal stem cells inhibit glioma growth Passage effect on aging of human umbilical cord derived mesenchymal stem cell Endothelial dysfunction in COVID-19: lessons learned from coronaviruses Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis Why is COVID-19 more severe in patients with diabetes? The role of angiotensin-converting enzyme 2, endothelial dysfunction and the immunoinflammatory system Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy MSC therapies for COVID-19: importance of patient coagulopathy, thromboprophylaxis, cell product quality and mode of delivery for treatment safety and efficacy Human adipose-derived mesenchymal stem cells modify lung immunity and improve antibacterial defense in pneumosepsis caused by Klebsiella pneumoniae Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial Combating COVID-19 with mesenchymal stem cell therapy Regulation of adaptive immunity; the role of interleukin-10 IL-10: a multifunctional cytokine in viral infections SARS-CoV-2 infection: The role of cytokines in COVID-19 disease Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung COVID-19 lockdown: de-risking exit by protecting the lung with leukaemia inhibitory factor (LIF) Immunomodulation by mesenchymal stem cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs The role of mesenchymal stromal cells in immune modulation of COVID-19: focus on cytokine storm Increased CD56bright NK cells in HIV-HCV co-infection and HCV mono-infection are associated with distinctive alterations of their phenotype Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19 Immunopathology of hyperinflammation in COVID-19 CXCR3 chemokine receptor contributes to specific CD8+ T cell activation by pDC during infection with intracellular pathogens Reduced CD4+T cell CXCR3 expression in patients with allergic rhinitis Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure Additional supporting information may be found online in the Supporting Information section at the end of this article.